Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idarubicin Dose Optimization in AML
NCT02277847Phase 4Unknown
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Mar 2010
- Primary completion
- Jun 2017
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of idarubicin in acute myeloid leukemia (AML) (2 arms), sponsored by Guangdong Provincial People's Hospital. Primary endpoints: Overall Survival at 5 years and Disease Free Survival at 5 years. Status: unknown.
02
Drugs
idarubicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02277847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02277847.